PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA — Lobbying Disclosure | Poliscope

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$564.4M

Filings

1,368

Firms Hired

Active Period

1999–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$26,610,000	67	22
2025	$37,900,000	90	22
2024	$31,000,000	93	23
2023	$27,090,000	85	22
2022	$28,290,000	93	22
2021	$29,570,000	85	21
2020	$25,520,000	81	20
2019	$35,120,000	80	19
2018	$27,520,000	76	19
2017	$25,430,000	79	21
2016	$25,440,000	62	16
2015	$18,320,000	43	11
2014	$16,510,000	47	12
2013	$17,740,000	56	14
2012	$18,410,000	46	11
2011	$18,790,000	52	12
2010	$21,740,000	47	13
2009	$26,150,520	48	13
2008	$20,220,000	49	13
2007	$22,733,400	23	11
2006	$18,100,000	18	9
2005	$7,220,000	9	8
2004	$7,480,000	9	6
2003	$8,480,000	8	5
2002	$6,200,000	5	4
2001	$11,280,000	8	4
2000	$3,500,000	6	4
1999	$2,040,000	3	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	$564,403,920	89
LESIC AND CAMPER COMMUNICATIONS	—	70
AKIN GUMP STRAUSS HAUER FELD	—	42
BGR GOVERNMENT AFFAIRS	—	73
THE MCMANUS GROUP	—	77
BRAVO GROUP	—	64
W STRATEGIES, LLC	—	66
EAST END GROUP, LLC	—	71
TCH GROUP, LLC	—	55
EMPIRE CONSULTING GROUP	—	64
MILLER STRATEGIES, LLC	—	39
TODD STRATEGY GROUP	—	43
CROSSROADS STRATEGIES, LLC	—	40
THORSEN FRENCH ADVOCACY LLC	—	64
BAKER & HOSTETLER LLP	—	24

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	1,225
SENATE	1,114
Health & Human Services, Dept of (HHS)	342
Executive Office of the President (EOP)	130
Centers For Medicare and Medicaid Services (CMS)	123
Food & Drug Administration (FDA)	106
U.S. Trade Representative (USTR)	80
Patent & Trademark Office (PTO)	72
Office of Management & Budget (OMB)	61
Commerce, Dept of (DOC)	60
White House Office	49
Natl Economic Council (NEC)	38
State, Dept of (DOS)	37
Office of the Vice President of the United States	24
Natl Security Council (NSC)	20
Congressional Budget Office (CBO)	17
Treasury, Dept of	17
Agency for Healthcare Research & Quality (AHRQ)	14
Medicare Payment Advisory Commission (MedPAC)	13
Federal Trade Commission (FTC)	9

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	767
Medicare/Medicaid	Medicare/Medicaid	541
Pharmacy	Pharmacy	383
Copyright/Patent/Trademark	Copyright/Patent/Trademark	312
Budget/Appropriations	Budget/Appropriations	247
Trade (domestic/foreign)	Trade (domestic/foreign)	209
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	51
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	44
Insurance	Insurance	21
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	12
Defense	Defense	10
Science/Technology	Science/Technology	8
Torts	Torts	6
Environment/Superfund	Environment/Superfund	4
Immigration	Immigration	3
Government Issues	Government Issues	3
Veterans	Veterans	2
Foreign Relations	Foreign Relations	2
Energy/Nuclear	Energy/Nuclear	1
Utilities	Utilities	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $30,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $30,000

Matched citations: S.1041

S. 1095119th Congress

Stop STALLING Act

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $30,000

Matched citations: S.1095

S. 1097119th Congress

Interagency Patent Coordination and Improvement Act of 2025

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Patent rights. Merchant rights. S.1097 - Interagency Patent Coordination and Improvement Act of 2025.

Client expense: — · Firm income: $30,000

Matched citations: S.1097

Show 21 more cited filings

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $30,000

Matched citations: S.2658

S. 43119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: THORSEN FRENCH ADVOCACY LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.

Client expense: — · Firm income: $30,000

Matched citations: S.43

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

Client expense: — · Firm income: $40,000

Matched citations: H.R. 1492

S. 1040119th Congress

Drug Competition Enhancement Act

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $40,000

Matched citations: S.1040

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: MARSHALL & POPP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Client expense: — · Firm income: $40,000

Matched citations: S.1041

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 1

H.R. 3152119th Congress

Patent Eligibility Restoration Act of 2025

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 3152

H.R. 3160119th Congress

PREVAIL Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 3160

H.R. 3269119th Congress

ETHIC Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 3269

H.R. 4121119th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 4121

H.R. 4570119th Congress

Interagency Patent Coordination and Improvement Act of 2025

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 4570

H.R. 4780119th Congress

USTRx Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 4780

H.R. 5304119th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 5304

H.R. 5342119th Congress

Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 5342

H.R. 6485119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 6485

H.R. 6500119th Congress

Continuing Appropriations and Extensions Act, 2027

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 6500

H.R. 6624119th Congress

Biological Intellectual Property Protection Act of 2025

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 6624

H.R. 6938119th Congress

Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 6938

H.R. 8646119th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 8646

H.R. 890119th Congress

Stopping Pharma’s Ripoffs and Drug Savings For All Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 890

H.R. 9102119th Congress

BINSA Act

2026 · third_quarter · Firm: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Client expense: $7,040,000 · Firm income: —

Matched citations: H.R. 9102

Source: Senate LDA